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ABSTRACT
Background: Bronchial smooth muscle (BSM) cells from asthmatic patients 
maintain in vitro a distinct hyper-reactive (“primed”) phenotype, characterized by 
increased release of pro-inflammatory factors and mediators, as well as hyperplasia 
and/or hypertrophy. This “primed” phenotype helps to understand pathogenesis of 
asthma, as changes in BSM function are essential for manifestation of allergic and 
inflammatory responses and airway wall remodelling. 
Objective: To identify signalling pathways in cultured primary BSMs of asthma 
patients  and non-asthmatic subjects by genome wide profiling of differentially 
expressed mRNAs and activated intracellular signalling pathways (ISPs). 
Methods: Transcriptome profiling by cap-analysis-of-gene-expression (CAGE), 
which permits selection of preferentially capped mRNAs most likely to be translated 
into proteins, was performed in human BSM cells from asthmatic (n=8) and non-
asthmatic (n=6) subjects and OncoFinder tool were then exploited for identification 
of ISP deregulations.
Results: CAGE revealed >600 RNAs differentially expressed in asthma vs control 
cells (p≤0.005), with asthma samples showing a high degree of similarity among 
them. Comprehensive ISP activation analysis revealed that among 269 pathways 
analysed, 145 (p<0.05) or 103 (p<0.01) are differentially active in asthma, with 
profiles that clearly characterize BSM cells of asthmatic individuals. Notably, we 
identified 7 clusters of coherently acting pathways functionally related to the disease, 
with ISPs down-regulated in asthma mostly targeting cell death-promoting pathways 
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INTRODUCTION
A major hallmark of the asthmatic airway wall is 
the increased bulk of airway smooth muscle (BSM) cells. 
In vitro, it has been shown that BSM cells of asthmatic 
patients have a distinct hyper-reactive (“primed”) 
phenotype, which is characterized by an increased release 
of pro-inflammatory factors and mediators, as well as 
hyperplasia and/or hypertrophy [1-3]. The “primed” 
phenotype of BSM cells might be pivotal to understanding 
the pathology of asthma, as changes in BSM function are 
essential for the manifestation of allergic and inflammatory 
responses and airway wall remodelling [4, 5]. 
Despite increasing evidence pointing to aberrant 
signalling mechanisms within BSM cells of asthmatic 
subject [6-8], only few studies have identified downstream 
signalling cascades that serve to control contractility 
and relaxation of BSM cells [9], BSM cell proliferation 
and apoptosis [7, 10, 11], as well as BSM cell-released 
extracellular components [12] and mediators that regulate 
immunity and angiogenesis [13]. The diversity of functions 
of BSM cells may thus modulate bronchomotor tone, 
airway hyper-responsiveness, as well as inflammatory 
and remodelling responses [14]. Together, this broad 
range of observations provide a rationale for regarding 
BSM cells as a major effector cells of the asthmatic lung 
and disturbed signalling in these cells as a major research 
target. 
We recently developed a new bio-informatics 
approach called OncoFinder, which enables quantitative 
measurement of intracellular signalling pathway (ISP) 
activation basing on gene expression data [15-17]. 
OncoFinder performs a quantitative measurement of the 
signalling pathway activation termed “pathway activation 
strength” (PAS) [15,18]. PAS measures the cumulative 
value of perturbations in a signalling pathway and serves 
as an indicator of pathological changes in the intracellular 
signalling machinery [19]. The PAS value itself serves as 
a new type of biomarker that can distinguish between the 
pathway activation profiles in different tissue types [20].
We have hypothesized and provided evidence 
that the “primed” phenotype of asthmatic BSM cells 
is reflected in the signalling pathway signature of the 
cells. Using small RNA profiling we recently identified 
deregulated phosphatase and tensin homolog (PTEN)/
phosphoinositide 3-kinase (PI3K)/Akt pathways in BSM 
cells of asthmatic patients as a candidate for a primed 
phenotype [21].
Here, we performed large-scale profiling of 
signalling pathway activation signatures in BSM cells 
of asthmatic and non-asthmatic subjects. Using the cap 
analysis of gene expression (CAGE) technique, which 
exclusively identifies 5’-capped mRNAs, complementary 
to RNA-seq [22], and therefore more accurately quantifies 
the proportion of mRNAs being translated into proteins, 
we compared the transcriptomes of primary BSM cells of 
asthmatic and non-asthmatic subjects. Our data show that 
unsupervised hierarchical clustering of CAGE tag cluster 
expression profiles as well as differentially activated 
ISPs, including the PTEN/AKT signalling system, clearly 
distinguished asthmatic from non-asthmatic samples.
RESULTS
Subjects characteristics
Patients with mild to moderate asthma (n = 8; 3 
females/5 males, age 23-77 years) had reversible airway 
obstruction documented in the past with median FEV1 
of 75.3% of the predicted value (ranging from 35.2% 
to 86.7%; Table 1). Cross-sections of human airway 
wall tissue demonstrated a marked increase of the bulk 
of smooth muscle bundles in asthmatic relative to non-
asthmatics (data not shown).
Cap analysis of gene expression (CAGE) of 
asthmatic and normal BSM cells
In order to isolate 5’-capped RNA, we constructed 
CAGE libraries using total RNA of BSM cells from 
asthmatic and controls subjects [23]. On average, 
24 millions of reads were obtained for each library 
(Supplementary Table S1). Since a key step of CAGE 
library preparation is the enzymatically cleavage of 
5’-adapter-ligated double-stranded cDNAs with Type III 
restriction endonuclease EcoP15I, which cleaves 27nt 
apart from its binding site, placed at the 3’end of adapter 
sequence, CAGE libraries should have basically the same 
read length after adapter trimming. To evaluate if this was 
true also for the libraries made for this study, we analysed 
distribution of sequenced read lengths after adapter 
trimming, confirming that the majority of the sequenced 
reads did have the expected length of 27 base pairs 
(Supplementary Figure S1A). Confirming the high quality 
of obtained reads is also the fact that average sequence 
quality scores (PHRED scores) was >30 (Supplementary 
Figure S1B).
and up-regulated ones affecting cell growth and proliferation, inflammatory response, 
control of smooth muscle contraction and hypoxia-related signalization. 
Conclusions: These first-time results can now be exploited toward development 
of novel therapeutic strategies targeting ISP signatures linked to asthma 
pathophysiology.
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Transcriptional landscape of asthma BSM cells
The analysis of distribution of distances between 
CAGE tags and the closest 5’ end of annotated transcripts 
is reported in Figure 1A. The histogram in the figure shows 
number of tags mapped to the first 50 bases upstream or 
downstream of known TSSs (column “0”), next columns 
to the left and right of “0” show number of tags that map 
between 51 and 100 bases downstream from TSS in both 
directions (being genes encoded in either DNA strand) and 
so on, up to 500 bp (0.5 kbp). The data shown represent 
number of tags upstream and downstream to TSSs, 
mapped at the following distances: 501 to 1.000 bp (1 
kbp), 1.001 to 5.000 bp (5 kbp), 5.001 to 50.000 bp (50 
kbp) or 50.001 to 500.000 bp (500 kbp) away from TSSs. 
The analysis led to mapping of the CAGE tags within or 
proximal to >5,600 documented transcription start sites 
(TSSs). As the distance from TSSs increased, a significant 
decrease in mapped CAGE tags can be observed (Figure 
1A), as expected for this type of analysis. Differential 
expression analysis revealed a total of 614 differentially 
expressed CAGE tag clusters (CTCs; p-value ≤0.005), 
including 515 down-regulated and 99 are up-regulated in 
BSM cells from asthma patients (see Supplementary Table 
S2, that includes also FDR values). Analysis of transcripts 
associated with differentially expressed CTCs showed 
that 84% of them represent protein coding mRNAs and 
16% corresponding to noncoding, or intergenic, transcripts 
(Figure 1B). For tags mapped to coding mRNAs, CTCs 
associated to promoters (defined as the region spanning 
from 1 to 500 bp upstream of the gene) of annotated 
transcripts, or to the 5’ UTR, exons, introns and 3’UTRs 
were identified. Out of 515 CTCs aligning to mRNAs, 
327, 64, 65, 49 and 10 derive from TSS-proximal regions, 
5’ UTRs, exons, introns or 3’ UTR/transcriptional 
termination sites (3’UTR_TTS in the figure), respectively 
(Figure 1B). Unsupervised hierarchical clustering analysis 
based on tag clusters expression was performed with 
the Ward’s agglomeration method, operated on Kendall 
correlation distance measures. It demonstrated that 
asthma and control samples cluster in two widely separate 
groups, with samples showing in each case a very similar 
expression profile among them. Results of this analysis are 
summarized in Figure 1C, where each row corresponds to 
one transcript and each column corresponds to one sample. 
Red and blue lines below the heatmap mark asthma and 
control samples, respectively.
Building intracellular signalling pathway 
activation profiles
The normalized gene expression levels of six non-
asthmatic and the eight asthmatic subjects are shown in 
Supplementary Table S3. These data were processed using 
the OncoFinder algorithm to establish pathway activation 
strength (PAS) profiles. We analysed the activation status 
of 269 intracellular signalling pathways (described 
in Supplementary Table S4). The PAS data, together 
with corresponding p-values and FDRs, are shown in 
Supplementary Table S5. Basing on these results, we built 
hierarchical clustering heatmap with Euclidean distance 
and average linkage for all the samples investigated 
(Figure 2A). It is clear that asthmatic and non-asthmatic 
BSM samples display two distinct and isolated clusters. 
This indicates that asthma is associated with multiple 
common changes in signalling pathway activation; 
changes that are shared by all (or the most) of the asthma 
samples. This observation was confirmed by the Principal 
Component Analyses, where asthma samples formed an 
unmistakably defined group in the plot (Figure 2B).
Table 1: Characteristics of asthma patients (All Caucasian)
Sample N Diagnosis Age Gender FEV11(%) Treatment
638 Asthma 34 Male 86.7 None
662 Asthma 36 Male 76.2 Symbicort2 (=ICS3+LABA4)
667 Asthma 51 Female 58.2 None
669 Asthma 23 Male 75.3 Symbicort (=ICS+LABA)
670 Asthma 37 Female ND None
695 Asthma 56 Male 87.4 None
738 Asthma 77 Female 41.2 None
739 Asthma 64 Male 35.2 Symbicort (=ICS+LABA)
1FEV1 – Forced Expiratory Volume in 1 second
2Symbicort - a combination of anti-inflammatory and bronchodilator medicines.
3ICS – Inhaled Corticosteroids
4LABA – Long-Acting Beta Agonists
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Functional significance of pathway activation 
analysis
For 145 (p<0.05) and 103 (p<0.01) pathways, we 
detected their differential activation between asthmatic 
and non-asthmatic BSM cells (Supplementary Table S5). 
The major part of the differentially activated signalling 
pathways (136/145; 94%) were up-regulated in asthma, 
whereas only 9/145 (6%) were down-regulated. Down-
regulated pathways in asthma mainly represented cell 
death-promoting pathways, whereas the up-regulated 
ones were predominantly involved in cell growth and 
proliferation, inflammatory response and some specific 
reactions, including smooth muscle contraction and 
hypoxia-associated signalling. The individual data 
points of all 269 investigated ISPs are presented in 
Figure 1: BSM transcription start sites recapitulate known transcription initiation and reveal gene expression 
modulation in asthma. A. Distribution of distances between CAGE TSSs and the closest 5’ end of a transcript annotated in Ensembl 
database. B. Histogram summarizing the proportion of differentially expressed CAGE tag clusters (CTCs) aligned to non-coding transcripts 
or intergenic regions and to protein-coding transcripts. C. Unsupervised hierarchical clustering of differentially expressed CTCs.
Oncotarget25154www.impactjournals.com/oncotarget
Supplementary Table S4. As demonstrated in Figure 3, 
the correlation plot of the activities of 269 intracellular 
signalling pathways identified 7 clusters of co-regulated 
pathways among the 14 investigated samples. The identity 
of signalling pathway that form the 7 distinct clusters are 
offered in Supplementary Table S6. Finally, we constructed 
a heatmap and determined correlation coefficients between 
the clusters to identify functional interactions. As shown 
in Figure 4, the activities of clusters 1 and 2 are positively 
correlated with each other, but negatively with the 
activities of clusters 5, 6 and 7. Likewise, the activities of 
clusters 5, 6 and 7 are positively correlated to each other, 
but negatively correlated to clusters 1 and 2.
DISCUSSION
This study is the first to systematically profile 
differentially activated ISPs in cultured primary human 
BSM cells from asthmatic and non-asthmatic subjects 
Figure 2: Modulation of signalling pathway activity in asthma A. Hierarchical clustering heatmap based on the analysis of 269 
intracellular signalling pathway activation profiles. Color key represents PAS score for a given pathway in a given sample. B. Results of the 
principal component analysis. Six non-asthmatic and eight asthmatic BSM samples were analysed according to their PAS score signatures 
calculated for 269 intracellular signalling pathways. Blue dots denote normal samples, red – asthmatic samples.
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using the CAGE technique, highlighting asthma-specific 
co-regulatory patterns. The 5’-capping of transcribed 
RNAs is a fundamental prerequisite for RNAs to be 
translated into proteins, as translation commences with 
binding of eIF4F protein complex to mRNA 5’-end cap 
(m7GpppN, where N is any nucleotide and m is a methyl 
group), followed by mRNA 5’UTR region unwinding that 
further facilitates binding to the 40S ribosomal subunit 
[24]. Thus, analysis of 5’-capped RNAs, rather than of 
the entire RNA pool, has the advantage that it focuses 
only on translation-ready RNAs, excluding non-coding 
RNAs and pseudo-genes, which are often difficult to 
distinguish from protein-coding gene transcripts. The 
exclusive identification of 5’-capped mRNAs provided 
us expression datasets better matching protein expression 
levels in the BSM cells.
The distribution of distances between CAGE tags 
and the closest 5’ end of annotated transcripts (Figure 
1A) demonstrated that the vast majority of CAGE tags 
for all expressed transcripts mapped within 50 bases from 
the known TSSs of corresponding genes, which is in 
agreement with typical tag distribution profile generally 
obtained for CAGE libraries [25]. The proportion of 
CAGE tags mapped at the distance of 50 to 500 kbp to 
the closest known TSSs may represent unannotated genes.
Differential expression analysis showed that, 
with 614 differentially expressed transcripts (p≤0.005), 
the expression profiles of the transcripts are distinctly 
different between asthma and control BSM cells. Of those, 
515 were down- and 99 were up-regulated in asthma 
(Figure 1C and listed in Supplementary Table S2 which 
also shows the FDR values for each gene). Analysis of 
the nature of transcripts associated with differentially 
expressed CTCs showed that 16% represented non-
coding or intergenic RNAs, whereas 84% coded for 
protein (Figure 1B). Further, unsupervised hierarchical 
clustering analysis revealed that the asthmatic patients 
can be clearly distinguished from control subjects based 
on CTC expression patterns (Figure 1C). Noteworthy, 
the dendrogram presented above the heatmap indicates 
that the distance between samples of the same group 
(asthma or control) is much smaller than the distance 
between samples of different groups, hence confirming 
that BSM cells of asthmatic and non-asthmatic subjects 
Figure 3: Signalling pathways correlation plot. Correlation plot of the activities of 269 intracellular signalling pathways among 
the fourteen investigated normal and asthmatic BSM tissue samples. Seven clusters of commonly regulated pathways are indicated on the 
figure. Color key represents correlation coefficients between the pathways ranging from -1 to 1. 
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really form two distinct populations. Of the 269 pathways 
we investigated, a significant fraction was differentially 
activated in asthmatic BSM cells, the majority being 
more active. As observed for the CMC signatures, the 
pathway activation data (heatmap, Figure 2A) also clearly 
distinguished between BSM cells of asthmatic and non-
asthmatic subjects. In accord with our previous studies 
analysing small noncoding RNA expression patterns [21], 
the PTEN/AKT signalling system was again amongst the 
most affected ISPs. 
The down-regulated pathways in asthma 
predominantly represented cell death-promoting pathways, 
whereas up-regulated pathways generally induce or 
enhance cell proliferation and growth, vascularization, 
inflammatory response and muscle-tissue specific 
responses, such as contractility. Moreover, we show 
here, for the first time, that the activity of 135 signalling 
pathways forms seven clearly distinguishable clusters, 
each characterized by concordant activation signatures 
of the underlying pathways. Only a tiny fraction of this 
clustering can be explained by similarities in gene content 
between the pathways. This suggests a true functional 
coordination between the cluster members. Further 
analysis of these functional clusters in view of building 
“super-pathways” - accumulating concordant functionally 
linked signalling pathways - goes beyond the aim of this 
study (molecular interactions in asthma), but our study 
showed that such is possible and may be potentially of 
great biological significance.
The hierarchical clustering and principal component 
analyses demonstrated that the asthmatic BSM samples 
form more tight clusters relative to the non-asthmatic 
controls (Figure 2B). This means that asthma is 
characterized by a more uniform signalling pathway 
activation signature than for the non-asthmatic condition 
samples. This is an intriguing and unexpected finding, 
because asthma is generally regarded as a heterogeneous 
pulmonary disorder involving many cell types [26], 
numerous genetic associations [27], and the disease 
can manifest itself as several different phenotypes [28]. 
Our data now indicate that, despite this heterogeneity, 
disturbed molecular signalling mechanisms of BSM cells 
are highly similar among individual asthma patients: 
Asthmatic BSM cells are more similar to each other than 
control cells are to each other, indicating similar molecular 
changes causing an asthma phenotype. The uniformity of 
Figure 4: Heatmap of the functional interactions between the signalling pathway clusters. Clusters are given from 1 to 7 
(left to right and top down). Correlation coefficients between the Clusters activation profiles vary in the interval from -1 till 1, corresponding 
to variation from dark red till dark blue on the heatmap, according to the defined color key.
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signalling pathway activation may reflect the common 
manifestation of airway constriction and BSM hyperplasia 
present in all asthma patients. Importantly, this observation 
envisages accomplishment on finding a set of universal 
anti-asthmatic molecular targets in the future. 
Up-regulated pathways were mostly responsible for 
promotion of cell growth (e.g., mTOR, IGF1R, Growth 
Hormone pathways), survival (e.g., Akt pathway, cellular 
anti-apoptotic mechanisms) and proliferation (e.g., Ras, 
MAPK, Spindle assembly and chromosome separation 
pathways), enhanced vascularization (VEGF pathway), for 
inducing inflammatory response (IL2, IL6, IL10, CD40, 
Interferon pathways) and other processes like increased 
muscle contractility (Muscle contraction-specific branch 
of cAMP pathway). Asthma samples were also enriched 
in the activities linked with RNA transcription (e.g. 
Transcription of RNA pathway and RNA polymerase II 
complex) and protein translation (e.g. branch of mTOR 
pathway positively regulating translation and positive 
regulation of translation initiation via eIF4F translation 
factor pathway). We also detected increased proteasome-
mediated protein degradation (ubiquitin-proteasome 
pathway) and enhanced autophagy (PPAR pathway) in 
asthma BSMs. Although PPARgamma has been shown to 
be increased in BSM asthma after mitogenic stimulation, 
it was not related to the increased proliferation observed in 
asthmatic BSM [28]. In contrast, pathways preventing cell 
growth (SMAD pathway branch leading to degradation 
of cell surface receptors of growth factors), promoting 
cell cycle arrest (PTEN pathway), cell death (Caspases 
cascade and Mitochondrial apoptosis pathway), were 
significantly down-regulated in asthmatic samples 
(Supplementary Table S5; description of pathways is given 
in Supplementary Table S4). Together, these observations 
provide a rational for the observation that in vitro cultured 
BSM cells of asthma patients grow faster than their non-
asthmatic counterparts [3, 7, 29] and may thus explain the 
in vivo observation of the increased bulk of BSM cells 
present in the airway wall.
Among the affected signalling processes, some 
were single pathways (e.g., Notch and EGFR pathways 
enhanced in asthma), whereas others were represented 
by multiple terminal branches of the same pathway 
(e.g. Glucocorticoid hormone pathway and its four 
terminal branches upregulated in asthma; Integrin 
linked kinase (ILK) pathway and its eleven terminal 
branches upregulated in asthma; Supplementary Table 
S5). Importantly, many of the pathways presented in 
Supplementary Table S5 do not come as a surprise, since 
they have previously been reported in association with 
asthma. Among them are those that are associated with 
β2-adrenoceptor agonists (e. g. GPCR-, cAMP-, CREB-
, RAS- and p38-pathway) and glucocorticosteroids (e. g. 
androgen hormone-, IP3-, RAS-, and mTOR-pathway), 
as well as the more general cell activation cascades 
induced by growth hormones, cytokines and chemokines 
(e. g. chemokine-, JNK-, PAK-, p38-, ERK-and Jak/
Stat-pathway). The androgen hormone pathway is of 
particular interest, since glucocorticosteroids (GS) are 
known to reduce airway contraction through altering 
calcium mobilization or Na+/K+ ATPase potentiation. GS 
also alter the formation of IP3 and cAMP levels through 
down-regulation and/or uncoupling of G-protein coupled 
receptors, thus exerting profound effects on the secretory 
and proliferating activity of BSM cells (reviewed in [30]). 
Indeed, glucocorticoids are very effective in reducing 
the proliferation of BSM cells [31]. Likewise, the anti-
mitogenic effects induced by GCPR-cAMP system involve 
numerous pathways, including inhibition of ERK1/2 and 
phosphoinositide 3′-kinase (PI3K), via PKA activation 
and Epac in BSM cells [reviewed in [32]]. The blue shift 
observed for the cAMP pathways in BSM cells of asthma 
patients, which indicates reduced activity, is in accord with 
reports showing a deficiency of the GPCR-cAMP-coupled 
signalling systems in BSM cells of asthma patients [33, 
34]. 
Our unbiased, hypothesis-free high-throughput 
approach enabled us to uncover several additional 
molecular signalling pathways that have never been 
published in association with asthma. Here, the ILK 
pathway stands out with eleven up-regulated branches. 
Integrin-linked kinase (ILK) is a multi-domain protein 
kinase that binds to the cytoplasmic tail of beta-integrins 
and has been identified as an important mediator of 
signalling pathways that regulate the growth and 
differentiation state of airway smooth muscle. ILK 
protein overexpression in BSM cells results in smooth 
muscle-specific regulation of gene and protein expression 
[35]. Another signalling pathway of interest is the Aryl 
Hydrocarbon Receptor (AHR) pathway, which according 
to our results is characterized by five up-regulated 
branches. The AHR is a member of the bHLH (basic 
Helix-Loop-Helix)-PAS (PerARNT-Sim) family of 
transcriptional regulators, which has been described to be 
involved in allergic [36] and lung-inflammatory responses 
[37]. Up-regulation of estrogen pathway represents 
another intriguing observation as well as this pathway 
is elicited by estrogen receptors and linked –again—to 
the cAMP pathway to reduce intracellular Ca2+ levels, 
thus promoting bronchodilation [38]. Finally, we should 
mention that the nine-branched HIF-1α/Hypoxia pathways 
were up-regulated in BSM cells of asthma patients. These 
pathways are associated with and/or promote tissue 
remodelling processes, including extra-cellular matrix 
deposition, angiogenesis and cell proliferation. All these 
aforementioned pathways are unexpectedly up-regulated 
in BSM cells of asthma patients and might hence clarify 
their primed phenotype [1-5].
The hierarchical clustering analysis (Supplementary 
Figures S3 and S4) showed that the activity of 145 
signalling pathways forms 7 clearly defined clusters, each 
characterized by concordant activation signatures of the 
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enclosing pathways (Figure 3 and Supplementary Figure 
S2). Although congruent activation might be explained 
by the similarities in gene content between the cluster-
forming pathways (e.g. AKT pathway terminal branches 
from cluster 1 or from cluster 2, or ILK pathway branches 
from cluster 3), most clusters represent the true functional 
coordination between the cluster members. Interestingly, 
the regulation of different functional clusters could be 
either congruent or opposed to each other (Figure 4). 
Unexpectedly, some clusters enclose pathways having 
rather opposite molecular functions. For example, Cluster 
1 (Supplementary Table S6) includes two pathways 
leading to apoptosis: a branch of mitochondrial apoptosis 
pathway and an apoptotic branch of NGF pathway. They 
are compensated by the two anti-apoptotic branches 
of AKT pathway from the same cluster, one – directly 
inhibiting apoptosis, and another – promoting expression 
of cell survival genes. Moreover, Cluster 1 includes 
two additional pathways which attenuate cell growth 
and proliferation: a branch of GSK3 pathway leading 
to degradation of Beta-Catenin and a branch of SMAD 
pathway responsible for degradation of growth factor 
membrane receptors. These activities are, in turn, met 
by the cell growth and proliferation-promoting pathways 
from the same cluster: a branch of AKT that activates 
ERK signalling, and a branch of cAMP pathway that 
degrades cell cycle checkpoint regulators. Something 
similar may account for the other Clusters. For instance, 
in Cluster 2 a plethora of cell growth-, proliferation- and 
survival–promoting terminal branches of AKT pathway 
are juxtaposed to a cell cycle arrest-promoting pathway 
SMAD. Further in-depth analysis of all functional clusters 
may reveal previously unknown functional ensembles of 
tightly co-regulated signalling pathways.
In conclusion, our study is the first to explore the 
complete assortment of signalling pathways activated 
in primary human BSM cells of asthmatics relative 
to non-asthmatic subjects and provides a basis to 
understand the “primed” phenotype of asthmatic BSM 
cells. This exploration may be pivotal to development 
of novel therapeutic strategies that specifically address 
the pathways associated with pathophysiology of 
bronchomotor tone, airway hyper-responsiveness, as well 
as airway inflammation and airway remodelling.
MATERIALS AND METHODS
Tissue specimens and cell cultures
Lung tissue specimens were obtained from 
the Department of Internal Medicine, Pulmonology, 
University Hospital Basel, Basel, Switzerland with the 
approval of the local ethical committees and written 
consent of all patients. Primary BSM cultures were from 
non-asthmatic donors (selection criteria are listed in 
the Eurotransplant guidelines and include the absence 
of primary lung disease, such as asthma and chronic 
obstructive pulmonary disease (COPD), and ≤20 pack 
yr of smoking history). BSM cells were established as 
previously described [3] and grown in RPMI 1640 (Lonza, 
Basel, Switzerland) supplemented with 5% fetal calf 
serum (FCS), 8 mM L-glutamine, 20 mM hydroxyethyl 
piperazine ethane sulfonic acid and 1% modified Eagle’s 
medium vitamin mix (Gibco, Paisley, UK). Neither 
antibiotics nor antimycotics were added at any time.
RNA isolation
RNA isolation was performed with mirVana miRNA 
isolation kit (Ambion, Life Science, Zug, Switzerland) as 
described earlier [39]. For more details see Supplementary 
Material.
CAGE sequencing and data analysis
Identification of primary BSM cells transcriptomes 
was performed by next-generation sequencing that 
allows a dynamic range of detection and measurement 
of relatively limited differences in expression between 
samples. CAGE library preparation was performed 
essentially as described [23]. For more details see 
Supplementary Material. 
Raw sequencing data are available in NCBI Gene 
Expression Omnibus (GEO) database (http://www.ncbi.
nlm.nih.gov/gds/) with Accession Number GSE63744.
Differential expression analysis and pathway 
analysis
Raw reads were filtered by quality >30 score 
through FASTX toolkit [40] and then trimmed at 5‘ and 3‘ 
in order to remove index and adapter. Only the remaining 
reads were used for alignment with the human genome 
assembly (GRCh37) where we employed TopHat v2.0.14 
[41]. CAGE tags were aligned to the human genome and 
the location of each tag respect to the nearest transcript 
annotated in Ensembl database [42] was calculated. The 
expression value of tags that aligned to multiple loci was 
distributed between these according to the weighting 
strategy of TopHat [41]. As promoters can vary in 
architecture, with some transcription units showing a 
strong preference for a particular base composition in its 
transcription initiation, and others using a broad collection 
of transcription start sites (TSSs) within a region of 
approximately 100 bases, TSSs have been clustered 
together when they mapped within 20 bases from each 
other [43]. Transcript expression values were normalized 
for each sample, resulting in values expressed in cluster 
Oncotarget25159www.impactjournals.com/oncotarget
tags per million (tpm). For more detailed description of 
methods used for differentially expression analysis see 
Supplementary Material. 
Source datasets
The signalling pathways knowledge base developed 
by SABiosciences (http://www.sabiosciences.com/
pathwaycentral.php) was used to determine structures of 
intracellular pathways, which were used for OncoFinder, 
as described previously [15, 16].
Functional annotation of gene expression data
For the functional annotation of the primary gene 
expression data, we applied our original algorithm 
termed OncoFinder [15, 16]. It enables calculation of the 
Pathway Activation Strength (PAS), a value which serves 
as a qualitative measure of pathway activation. Briefly, 
the enclosing algorithm utilizes the following formula to 
evaluate pathway activation: 
Here, the case-to-normal ratio (CNRn) is the ratio 
of expression levels for a gene n in the sample under 
investigation to the same average value for the control 
group of samples. The Boolean flag of BTIF (beyond 
tolerance interval flag) equals to one for genes with 
significantly altered expression, and to zero for non-
significantly affected genes. The applied significance 
criteria were as follows: differential gene had to meet 
simultaneously the two conditions, first, gene expression 
level for the sample must lie outside the tolerance interval 
(p<0.05), and second, the value of CNR must differ from 
1 considerably, thus being inferior of 0.66 or exceeding 
1.5. The discrete value of ARR (activator/repressor role) 
reflects the functional role of a protein n in the pathway 
[15, 16].
Statistical tests
The PAS values for each normal sample were 
obtained using the whole set of these normal samples as 
a reference. Distribution of PAS values was estimated, 
assuming its Gaussian behaviour. Then, for each pathway 
of each asthma sample, a probability that its PAS value 
comes from this estimated distribution was calculated. 
Additionally, p-values and FDRs for each pathway of 
the entire group of asthma samples were calculated using 
Wilcoxon rank-sum test and Benjamin & Hochberg 
method, respectively. Principal component analyses were 
performed using MADE4 package [44]. Hierarchical 
clustering heatmaps with Pearson distance and average 
linkage were generated using heatmap.2 function from 
“gplots” package [45]. Pearson tau correlation matrix 
was calculated in R 3.1.1 using a function of standard 
library “cor” with the default settings. Correlation diagram 
was built using a function “corrplot” from the package 
“corrplot” sorted with respect to hierarchical clustering. 
Similarities between the pathways according to the content 
of similar genes were calculated using Jaccard coefficient. 
The Jaccard coefficient measures similarity between finite 
sample sets, and is defined as the size of the intersection 
divided by the size of the union of the sample sets.
Abbreviations
BSM – bronchial smooth muscle; CAGE – cap 
analysis of gene expression; CTC – CAGE tag cluster; 
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in 1 second; PAS – pathway activation strength; UTR – 
untranslated region.
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Clinical implications
Capped RNA expression profiling followed by 
system biology analysis reveals asthma-specific signalling 
pathway deregulation. This holds the promise of precision 
medicine and accurate therapy selection.
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